Enhancing ARIC Infrastructure to Yield a New Cancer Epidemiology Cohort

加强 ARIC 基础设施以产生新的癌症流行病学队列

基本信息

批准号：
8469418
负责人：
ELIZABETH A. PLATZ
金额：
$ 55.63万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-05-15 至 2017-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8469418
关键词：
Address African American Archives Area Arts Atherosclerosis Authorization documentation Award Biological Markers Blood Blood specimen Breast Cancer Research Infrastructure Cessation of life Clinical Colon Communities Consent Contracts Cost Savings DNA Sequence Data Death Certificates Diabetes Mellitus Diagnosis Discipline Epidemiologic Studies Epidemiologist Female Female breast Food Frequencies Funding Handedness Head Health Histology Hospitalization Hospitals Incidence Instruction Interview Life Style Link Location Malignant Neoplasms Malignant neoplasm of lung Measurement Measures Medical Medical Records Medicare Molecular Genetics National Heart, Lung, and Blood Institute Natural History Operative Surgical Procedures Organ Paper Participant Pathologic Pathology Pharmaceutical Preparations Prostate Protocols documentation Publishing Questionnaires Recontacts Records Recruitment Activity Recurrence Registries Research Research Infrastructure Research Personnel Resected Resources Retreatment Risk Schedule Site Specimen Staging Telephone Time Tissue Microarray Tissues Update Urine Variant Visit Washington Woman Work abstracting adjudicate aged anticancer research cancer diagnosis cancer epidemiology cancer recurrence cancer surgery cohort cost fasting glucose follow-up genome sequencing genome wide association study interest mortality neoplasm registry novel operation receptor response risk variant tissue processing working group

项目摘要

DESCRIPTION (provided by applicant): We propose to enhance the infrastructure of ARIC; the Atherosclerosis Risk in Communities, cohort to yield a new Cancer Epidemiology Cohort that brings novel features to cancer epidemiology research. In 1987, 15,792 participants aged 45-64 years were recruited from Forsyth Co., NC; Jackson, MS; Minneapolis, MN; and Washington Co., MD. 55% are women and 27% are African-American. Participants underwent 4 clinical exams; a 5th is scheduled for 2011. Blood and urine specimens have been banked, medications recorded, and a food frequency questionnaire completed. Participants were interviewed by phone annually and now semi-annually to obtain updated health information. The response at year 21 is 91%. Because ARIC has never been viewed as a Cancer Epidemiology Cohort and infrastructure and cost constraints, only cancer diagnosis has been systematically recorded. By 2006, 3,145 participants were diagnosed with an incident first primary and 376 with a 2nd / 3rd primary. Information, such as stage, grade, and histology, location in organ, laterality, receptor status, treatment, recurrence, and re-treatment, needed to address contemporary questions is not currently available. Tissue needed for molecular/genetic studies has not been collected. Thus, we propose: 1) Starting 2012, to prospectively identify cases from semi-annual phone interviews and collect medical/pathology records pertaining to cancer diagnosis, treatment, recurrence, and retreatment and tissue blocks. 2) To retrospectively collect information characterizing cancer diagnoses and recurrences before 2012 from cancer registries in the 4 ARIC states (consent already obtained) and medical records, and collect tissue blocks. By 2016, we expect 4,900 fully annotated incident cases. We established a Cancer Working Group to develop protocols for adjudicating cancer endpoints and prioritize research using the resource. With enhanced infrastructure, we expect that research questions such as these are addressable uniquely in ARIC: 1) What is the association between timing of the natural history of diabetes using 4 fasting glucose and 2 HbAlc measurements and timing of cancer diagnosis? 2) Using GWAS and sequencing data, is there a set of risk variants shared by major cancers or are variants specific to each site?

描述（由申请人提供）：我们建议增强ARIC的基础设施；社区的动脉粥样硬化风险是产生新的癌症流行病学队列的同类，该研究将新颖的特征带入了癌症流行病学研究。 1987年，从北卡罗来纳州福赛斯公司（Forsyth Co.）招募了15,792名45-64岁的参与者；杰克逊，女士；明尼苏达州明尼阿波利斯；和华盛顿公司，医学博士。 55％是女性，27％是非裔美国人。参与者接受了4项临床检查；计划于2011年举行第五名。已经记录了血液和尿液标本，并完成了一份食物频率问卷。参与者每年通过电话进行访谈，现在每半年一次以获取更新的健康信息。 21年的回应为91％。由于ARIC从未被视为癌症流行病学队列和基础设施和成本限制，因此仅系统地记录了癌症诊断。到2006年，有3,145名参与者被诊断出患有第一个初级事件，第二个初级诊断为376。目前尚不可用的信息，例如阶段，等级和组织学，器官中的位置，器官中的位置，横向性，受体状态，治疗，复发和重新治疗，目前尚不可解决当代问题。尚未收集分子/遗传研究所需的组织。因此，我们建议：1）从2012年开始，从半年度电话访谈中确定病例并收集与癌症诊断，治疗，复发以及撤退和组织块有关的医学/病理记录。 2）回顾性收集表征2012年以前从四个ARIC状态（已获得同意）和病历的癌症注册表中进行癌症诊断和复发的信息，并收集组织块。到2016年，我们预计有4,900例完全注释的事件案件。我们建立了一个癌症工作组，以开发用于裁定癌症终点的方案，并使用资源确定研究的优先级。随着基础设施的增强，我们期望诸如此类的研究问题在ARIC中是可以独特的：1）使用4种禁食葡萄糖与2 HBALC测量和癌症诊断的时间安排糖尿病自然史的时机之间的关联是什么？ 2）使用GWAS和测序数据，是否有主要癌症共享的一组风险变体或每个站点特定的变体？